Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bristol-Myers Squibb

49.82
+0.88001.80%
Post-market: 47.75-2.0700-4.15%19:59 EDT
Volume:13.38M
Turnover:661.72M
Market Cap:101.37B
PE:-11.29
High:50.06
Open:49.31
Low:48.88
Close:48.94
Loading ...

Cytokinetics reiterated as top pick at H.C. Wainwright, Camzyos updates positive

TIPRANKS
·
21 Apr

Bristol-Myers Says US FDA Updates Prescribing Information for Cardiac Myosin Inhibitor Camzyos

MT Newswires Live
·
21 Apr

Bristol-Myers Squibb’s Camzyos: Regulatory Easing vs. Looming Competition

TIPRANKS
·
21 Apr

Curious about Bristol Myers (BMY) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Zacks
·
18 Apr

Bristol Myers says FDA updates Camzyos label to simplify treatment

TIPRANKS
·
18 Apr

BRIEF-U.S. FDA Updates Camzyos Label To Reduce Echocardiography Monitoring Requirements And Contraindications

Reuters
·
18 Apr

U.S. Food and Drug Administration Updates Camzyos® (Mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications

THOMSON REUTERS
·
18 Apr

Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?

Zacks
·
18 Apr

BMO Capital Adjusts Bristol-Myers Squibb Price Target to $53 From $61

MT Newswires Live
·
18 Apr

Bristol Myers Squibb (BMY) Stock Moves -1.35%: What You Should Know

Zacks
·
17 Apr

Is Bristol-Myers Squibb Company (BMY) the Best Pharma Stock to Buy for Long Term Growth?

Insider Monkey
·
16 Apr

Bristol-Myers Squibb, Optellum Collaborate to Boost Early Lung Cancer Diagnosis

MT Newswires Live
·
15 Apr

BRIEF-Optellum Announces Agreement With Bristol Myers Squibb To Leverage Ai To Boost Early Lung Cancer Diagnosis

Reuters
·
15 Apr

BUZZ-Cytokinetics falls after rival Bristol Myers' heart drug fails trial

Reuters
·
15 Apr

Optellum Announces Agreement With Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

THOMSON REUTERS
·
15 Apr

Bristol-Myers Squibb Company (BMY): Among the Best Value Dividend Stocks to Buy According to Billionaires?

Insider Monkey
·
15 Apr

BRIEF-Bristol Myers Squibb Provides Update On Phase 3 ODYSSEY-HCM Trial

Reuters
·
15 Apr

BUZZ-Bristol Myers falls as heart disease drug fails in late-stage trial

Reuters
·
15 Apr

Bristol-Myers' Camzyos Phase 3 Trial Misses Dual Primary Endpoints

MT Newswires Live
·
15 Apr

CORRECTED-UPDATE 2-Bristol Myers' heart disease drug fails to meet main goals in late-stage study (April 14)

Reuters
·
15 Apr